Loading
PB
Pardes Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 06 Apr 2023.
Pardes Biosciences, Inc.: what insiders have been doing
Pardes Biosciences, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Pardes Biosciences, Inc. has had no insider filing for more than a year; the last one goes back to 31 August 2023.
Over the whole record (from 2021), the tally stands at 6 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
26
Thresholds
n/a
Buy Volume
€5M
6 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$83.2M
Last declaration on 31 August 2023
Declarations26 total
211,169 sharesCommon StockSEC:0001209191-23-047823:0
316,753 sharesCommon StockSEC:0001209191-23-047821:0
16,813,146 sharesCommon StockSEC:0001140361-23-042108:0
70,390 sharesCommon StockSEC:0001209191-23-047834:0
5,327,798 sharesCommon StockSEC:0001209191-23-047827:0
70,390 sharesCommon StockSEC:0001209191-23-047813:0
200,000 sharesCommon StockSEC:0001209191-23-047825:0
50,000 sharesCommon StockSEC:0001209191-23-047836:0
773,952 shares@ US$1.5067.2% of flowCommon StockSEC:0001213900-23-028116:0
Canonical exit: 4 Jul 2023 (T+90)
▲
Same trade as the filing by Foresite Capital Management V, LLC, counted once · View ↗
773,952 shares@ US$1.50100.0% of flowCommon StockSEC:0001213900-23-028117:0
Canonical exit: 4 Jul 2023 (T+90)
21,000 shares@ US$1.19100.0% of flowCommon StockSEC:0001209191-22-060671:0
Canonical exit: 8 Mar 2023 (T+90)
12,500 shares@ US$1.0934.1% of flowCommon StockSEC:0001209191-22-060154:0
Canonical exit: 5 Mar 2023 (T+90)
637,420 shares@ US$0.8532.8% of flowCommon StockSEC:0001213900-22-077637:0
Canonical exit: 1 Mar 2023 (T+90)
25,000 shares@ US$1.0465.9% of flowCommon StockSEC:0001209191-22-059677:0
Canonical exit: 1 Mar 2023 (T+90)
3,591,265 shares0Common StockSEC:0001209191-22-042848:0
4,941,250 shares0Class A Common StockSEC:0001213900-21-068107:0
4,941,250 shares0Common StockSEC:0000899243-21-050105:0
30,000 shares0Class A Common StockSEC:0001213900-21-068108:0
30,000 shares0Class A Common StockSEC:0001213900-21-068105:0
30,000 shares0Class A Common StockSEC:0001213900-21-068104:0
4,873,750 shares0Common StockSEC:0001213900-21-067728:0
52,500 shares0Class A Common StockSEC:0001213900-21-067726:0
52,500 shares0Class A Common StockSEC:0001213900-21-067729:0
52,500 shares0Class A Common StockSEC:0001213900-21-067727:0
1,000,000 shares@ US$10.0075.4% of flowCommon StockSEC:0000899243-21-049928:0
25 of 26 declarations
About Pardes Biosciences, Inc.
Pardes Biosciences, Inc. (ticker: PRDS) is a U.S.-based biopharmaceutical company that was listed on NASDAQ in the United States (United States). The company was built around a drug-discovery strategy combining reversible covalent chemistry with viral biology, with an initial focus on developing novel oral antiviral therapeutics. SEC filings show that Pardes was incorporated in Delaware on February 27, 2020, and that its principal executive office was in Carlsbad, California, placing it squarely within the Southern California biotech cluster. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000114036123040279/ny20010094x1_exa1a.htm?utm_source=openai))
Pardes’ core historical program was PBI-0451, later referred to as pomotrelvir, an oral direct-acting antiviral designed to inhibit the SARS-CoV-2 main protease (Mpro). The company’s public filings and press materials describe a development path that moved from discovery into the clinic, including the initiation of a first-in-human Phase 1 study in 2021. Strategically, the thesis was to create a convenient oral therapy that could treat or prevent COVID-19, potentially differentiating itself from more complex treatment options through simplicity of administration and a targeted mechanism of action. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000119312522021684/d299901ds1a.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, Pardes was a highly focused small-cap biotech, meaning its market position depended far more on clinical validation, regulatory progress, and capital access than on commercial scale. Companies in this category are typically valued on the basis of pipeline optionality, scientific differentiation, and intellectual property strength, rather than broad product revenue. Pardes therefore fit the profile of a development-stage company whose equity story was driven by execution risk and binary clinical milestones. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000095017023007860/prds-20221231.htm?utm_source=openai))
Geographically, the company was overwhelmingly U.S.-centric, with operations and leadership anchored in California. Its corporate history is also notable: Pardes reached the public markets through a business combination with FS Development Corp. II, after which the combined entity operated under the Pardes Biosciences name. In 2023, the company’s corporate path changed materially again, with a tender offer and subsequent delisting from NASDAQ, making its recent public-market profile more about corporate actions and ownership disclosures than ongoing listed-company operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000095017023007860/prds-20221231.htm?utm_source=openai))
For investors, PRDS should be viewed primarily as a biotechnology restructuring and event-driven case rather than a conventional commercial pharma company. The most relevant recent developments have centered on insider filings, governance events, and transaction history, while the underlying investment case has historically hinged on the fate of a single lead antiviral asset. That makes Pardes a classic high-risk, high-uncertainty biotech name where regulatory, clinical, and corporate developments matter more than traditional operating metrics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1822711/000119312523225526/d531376dsc14d9a.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
